Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes …

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics ...
Le Lézard

Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)

Sentynl Therapeutics Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences Limited ...
Science Daily

Physical signals as fate deciders: How mechanical forces extrude cells from tissues

Epithelial tissues are in constant interaction with their environment. Maintaining their functionality requires dynamic balance (homeostasis) and that their cell numbers are tightly regulated. This is ...

Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes ...

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 milli ...